GlobeNewswire

1002-039 Phase 2 Add-on to PCSK9i – Safety & Tolerability

Safety Tolerability

Overview of Adverse Events and Discontinuations
Format

PNG

Source

Esperion Therapeutics, Inc.

Downloads